Lucky you! Here's a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Global tensions are on the rise — that could be a good thing for Elbit Systems (ESLT)
- Why Electromed (ELMD) could be an undervalued gem
-
Flex (FLEX) earns Stock of the Week status — here’s why
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Get 3 Stocks Poised to Join the "Trillion Dollar" Club - FREE
Futurist Eric Fry has recommended 40+ stocks that have gone on to soar more than 1,000%.
Now, he's revealing 3 new AI stock picks he predicts could soon reach the coveted trillion-dollar milestone.
Only 10 companies in history have surpassed the $1T mark, but AI is accelerating wealth creation faster than ever before.
Get Eric Fry's research today and position yourself for what could be a very exciting ride to the top...
YES! Send me the names, tickers and research - FREE
Electromed makes medical devices for treating lung conditions. ELMD shares have shot up by 28.63% in the past month — however, the stock remains undervalued. The company has delivered 7 earnings beats in a row — and it has a balance sheet that is more than healthy enough to finance new growth.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $23.95 — get current quote >
Max 1-year forecast: $36.00
Why we’re watching:
- Electromed is currently tracked by 2 Wall Street analysts — both of whom issue Strong Buy ratings. See the ratings
- The average 12-month price forecast for ELMD shares currently stands at $35, and implies a 48.23% upside.
- Roth Capital researcher Kyle Bauser (a top 24% rated analyst) maintained a Strong Buy rating on the stock after the company reported its Q4 and FY 2025 earnings, and increased his price target from $29 to $35.
- Bauser referred to the quarter's results as "better-than-expected."
- Management outlined an expectation that FY 2026 will deliver double-digit revenue growth and expanded operating leverage.
- From an investment perspective, Bauser said the stock is highly undervalued in view of (1) the company's market-leading position in the underserved bronchiectasis space, and (2) the company's strong earnings profile, clean balance sheet, and improving operating efficiencies.
- Electromed shares currently rank in the top 4% of the equities that we track, giving them a Zen Rating of A.
- ELMD is currently trading at a price-to-earnings (P/E) ratio of 26.91x, which is below both industry and wider market averages. In terms of its Value Component Grade rating, the stock ranks in the 82nd percentile.
- With regard to its Sentiment Component Grade rating, Electromed ranks in the 87th percentile of equities.
- On top of that, ELMD ranks quite highly in Safety and Financials — in the top 4% and top 2% of stocks, to be exact. (See all 7 Zen Component Grades here >)
![]()
Elbit Systems develops advanced electronics and weapons systems used by militaries around the world. With global tensions on the rise and demand for high-tech defense solutions growing, Elbit’s diversified portfolio and international footprint position it as a key player in the modern defense industry.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $472.00 — get current quote >
Max 1-year forecast: $540.00
Why we’re watching:
- ESLT is a bit of an under-the-radar pick — the stock currently has just 1 analyst rating, which is a Strong Buy. See the rating
- Bank of America equity researcher Ronald Epstein (a top 9% rated analyst) maintained a Strong Buy rating on Elbit Systems after the company's Q2 2025 earnings. The BofA analyst also increased his price forecast from $500 to $540.
- Epstein said they raised their 2025 EPS estimate and multiple to account for the company's stronger-than-expected growth in the quarter and the multiple expansion for defense names, saying Elbit Systems continues to deliver on soaring demand.
- Elbit Systems shares rank in the 88th percentile of the equities that our system tracks, giving them a Zen Rating of B.
- ESLT also happens to rank in the 88th percentile when it comes to Growth and Safety.
- However, Momentum is the star of the show here — Elbit Systems stock has rallied by 83.02% since the start of the year. In terms of this category, the stock ranks in the top 3% of equities. (See all 7 Zen Component Grades here >)
![]()
Flex helps design, build, and deliver products and entire supply chains across a wide variety of industries, including automotive, healthcare, and even cloud computing. It also happens to be our Stock of the Week. Right now, this is one of the highest-rated stocks in the tech sector — as well as one of the best-rounded stocks we track overall.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $53.95 — get current quote >
Max 1-year forecast: $60.00
Why we’re watching:
- FLEX is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why the stock deserves inclusion in his exclusive, 20-stock strong Zen Investor portfolio in a Monday article.
- Flex operates in more than 30 countries — which allows it to not only take advantage of the best labor markets, but also to play the tariff situation to its advantage.
- Even if we disregard the aforementioned advantage, the company is incredibly well-run — having posted 20 (yes, twenty) consecutive earnings beats.
- Flex is the 6th highest-rated stock in the Electronic Component industry, which has an Industry Rating of A.
- FLEX ranks in the top 5% of the stocks that we track — giving it a Zen Rating of A, equivalent to a Strong Buy rating.
- Speaking of Strong Buy ratings, FLEX is a favorite of Wall Street analysts — the stock is currently tracked by 7 Wall Street researchers, all of whom issue Strong Buy ratings. See the ratings
- With that in mind, it won’t come as a surprise that the stock ranks in the top 13% when it comes to Sentiment.
- That isn’t FLEX’s strongest suit, however — that title belongs to Momentum, a category in which FLEX ranks in the top 11% of equities, thanks to a 38.92% year-to-date (YTD) rally. (See all 7 Zen Component Grades here >)
![]()
What to Do Next?